This practice is governed by Section 503A of the Federal Food, Drug, and Cosmetic Act
The details: In March 2024, Altimmune announced the results of MOMENTUM, a phase 2 trial in which people received weekly injections of pemvidutide as an obesity treatment
Other things that might interest you:
Food and Drug Administration (2024) Update on FDAs ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity
They went back, and they got in touch with 15 of their past customers, and they asked them if the injections had helped
If any provision of these Terms and Conditions of Use shall be held by a court of competent jurisdiction to be contrary to law, the remaining provisions of these Terms and Conditions of Use shall remain in full force and effect